english.prescrire.org > Spotlight > 100 most recent > Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the January issue of Prescrire International - Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

FREE DOWNLOAD In the "Reviews" section this month: what is dapagliflozin's harm-benefit balance in type 2 diabetes, in light of the results of a recent randomised, double-blind trial studying the drug's effect on cardiovascular outcomes?
Full text available for free download.

Summary

  • A randomised, double-blind trial of dapagliflozin versus placebo included more than 17 000 patients with type 2 diabetes, half of whom were followed for at least 4 years.
     
  • In this trial, dapagliflozin did not reduce the rate of cardiovascular complications of diabetes, or death.

Full text available for free download.

 ©Prescrire 1 January 2020

"Type 2 diabetes. Cardiovascular assessment of dapagliflozin: no advance" Prescrire Int 2020; 29 (211): 23. (Pdf, free).

Share Share on Facebook Share on Twitter
Share
Partager sur Facebook Partager sur Twitter

 
Download the full review
Pdf, free

See also:

Dapagliflozin. A hypoglycaemic
drug causing disproportionate
harm, especially to kidneys
Prescrire Int 2014;
23 (147): 61-64.
Pdf, subscribers only